摘要
神经退行性疾病(NDD)如阿尔茨海默病,帕金森氏病和亨廷顿氏病是一组异质性疾病,伴有神经元的进行性和严重性丧失。对于这些疾病没有完全的证据治疗,只有可以减轻某些症状的药物。为NDD开发有效的治疗方法是一项艰巨但必要的任务。因此,调查适用于许多NDD的目标的单萜类化合物具有高度相关性。许多单萜类化合物已经证明了由各种系统介导的有希望的神经保护活性。它可以形成制剂的基础,这对于减轻NDD症状和治疗疾病进展以及预防神经变性都是有用的。需要进一步开发包括检测具有高神经保护或神经营养活性的单萜类化合物及其衍生物以及合格临床试验的结果,以得出关于这些药物功效的可靠结论。
关键词: 乙酰胆碱酯酶抑制剂,阿尔茨海默病,大麻素,亨廷顿病,单萜,单萜类,神经保护活性,帕金森病。
Current Medicinal Chemistry
Title:Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders
Volume: 25 Issue: 39
关键词: 乙酰胆碱酯酶抑制剂,阿尔茨海默病,大麻素,亨廷顿病,单萜,单萜类,神经保护活性,帕金森病。
摘要: Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.
Export Options
About this article
Cite this article as:
Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders, Current Medicinal Chemistry 2018; 25 (39) . https://dx.doi.org/10.2174/0929867324666170112101837
DOI https://dx.doi.org/10.2174/0929867324666170112101837 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases
Current Neuropharmacology Repetitive Transcranial Magnetic Stimulation for ALS
CNS & Neurological Disorders - Drug Targets Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research From the Editors Perspective: Activity, Anoxia, Angiogenesis, and Alzheimers Disease
Current Neurovascular Research Stem Cell Regenerative Potential Combined with Nanotechnology and Tissue Engineering for Myocardial Regeneration
Current Stem Cell Research & Therapy In silico Modeling Studies of 5-HT2B Antagonistic Activity of 2-(2- phenylethyl)chromone Derivatives from Cucumis melo Seeds
Letters in Drug Design & Discovery Resolution-Associated Molecular Patterns (RAMPs) as Endogenous Regulators of Glia Functions in Neuroinflammatory Disease
CNS & Neurological Disorders - Drug Targets Impact of Early Life Stress on the Pathogenesis of Mental Disorders: Relation to Brain Oxidative Stress
Current Pharmaceutical Design Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Current Alzheimer Research The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design Insilico Analysis of Post-Translational Modifications in DRD2 Receptor Protein in Schizophrenic Patients
Current Proteomics Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Preparation of Hymenialdisine, Analogues and Their Evaluation as Kinase Inhibitors
Current Medicinal Chemistry Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism